- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Court supports Immunomedics patent
Biopharmaceutical firm Immunomedics of Morris Plains, NJ, announced last month that the District Court in the Hague upheld the company's European patent when it dismissed a legal action brought by Hoffman LaRoche. Basil, Switzerland-based LaRoche filed
Biopharmaceutical firm Immunomedics of Morris Plains, NJ, announced last month that the District Court in the Hague upheld the company's European patent when it dismissed a legal action brought by Hoffman LaRoche. Basil, Switzerland-based LaRoche filed the action in response to an infringement suit Immunomedics brought against it last fall. Immunomedics' European patent is valid in nine countries and covers CEA-specific antibodies as well as immunoassays which use CEA antibodies, according to the company's patent attorney, Bernhard Saxe of Foley & Lardner in Washington, DC.
In other Immunomedics news, the company last month reported that it has conferred a royalty-bearing, nonexclusive license to Dako A/S of Glostrup, Denmark, for its worldwide patents covering antibodies to CEA. Dako will sell the antibodies to pathology laboratories that stain tumor specimens for CEA.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
